Pierre V. Trân

2.6k total citations · 1 hit paper
28 papers, 1.9k citations indexed

About

Pierre V. Trân is a scholar working on Psychiatry and Mental health, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Pierre V. Trân has authored 28 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Psychiatry and Mental health, 18 papers in Pharmacology and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in Pierre V. Trân's work include Schizophrenia research and treatment (19 papers), Treatment of Major Depression (18 papers) and Electroconvulsive Therapy Studies (7 papers). Pierre V. Trân is often cited by papers focused on Schizophrenia research and treatment (19 papers), Treatment of Major Depression (18 papers) and Electroconvulsive Therapy Studies (7 papers). Pierre V. Trân collaborates with scholars based in United States, Chile and Argentina. Pierre V. Trân's co-authors include Gary D. Tollefson, Charles M. Beasley, S.H. Hamilton, Scott W. Andersen, Janet H. Potvin, Amy J. Kuntz, Mary Anne Dellva, Robert K. McNamara, Frank P. Bymaster and Michael J. Detke and has published in prestigious journals such as Biological Psychiatry, The British Journal of Psychiatry and Journal of Affective Disorders.

In The Last Decade

Pierre V. Trân

27 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders

1997 567 citations Pierre V. Trân, S.H. Hamilton et al. Journal of Clinical Psychopharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pierre V. Trân United States	17	1.5k	616	304	297	175	28	1.9k
G.D. Tollefson United States	17	1.1k 0.8×	455 0.7×	232 0.8×	442 1.5×	183 1.0×	76	1.6k
P. Tran United States	10	1.2k 0.8×	453 0.7×	266 0.9×	292 1.0×	81 0.5×	22	1.9k
W. Rein France	16	1.1k 0.7×	469 0.8×	215 0.7×	199 0.7×	196 1.1×	48	1.5k
Caroline Corves Germany	6	1.7k 1.1×	311 0.5×	369 1.2×	360 1.2×	138 0.8×	11	2.2k
S.H. Hamilton United States	18	2.4k 1.6×	725 1.2×	598 2.0×	483 1.6×	201 1.1×	41	3.0k
Ibrahim Turkoz United States	22	1.3k 0.9×	566 0.9×	199 0.7×	411 1.4×	184 1.1×	98	1.8k
Raymond Sanchez United States	31	2.6k 1.8×	1.0k 1.7×	284 0.9×	498 1.7×	192 1.1×	68	3.3k
Claudia Leucht Germany	14	1.2k 0.8×	286 0.5×	333 1.1×	410 1.4×	162 0.9×	20	1.6k
Mirza W. Ali United States	16	2.0k 1.4×	396 0.6×	292 1.0×	283 1.0×	54 0.3×	30	2.6k
W.W. Fleischhacker Austria	27	1.5k 1.0×	409 0.7×	290 1.0×	387 1.3×	87 0.5×	58	2.5k

Countries citing papers authored by Pierre V. Trân

Since Specialization

Citations

This map shows the geographic impact of Pierre V. Trân's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre V. Trân with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre V. Trân more than expected).

Fields of papers citing papers by Pierre V. Trân

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre V. Trân. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre V. Trân. The network helps show where Pierre V. Trân may publish in the future.

Co-authorship network of co-authors of Pierre V. Trân

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre V. Trân. A scholar is included among the top collaborators of Pierre V. Trân based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre V. Trân. Pierre V. Trân is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nemeroff, Charles B., Alan F. Schatzberg, D. Goldstein, et al.. (2025). Duloxetine for the Treatment of Major Depressive Disorder. Psychopharmacology Bulletin. 36(4). 106–132. 1 indexed citations

Bogan, Richard, Michel A. Cramer Bornemann, Clete A. Kushida, Pierre V. Trân, & Ronald W. Barrett. (2010). Long-term Maintenance Treatment of Restless Legs Syndrome With Gabapentin Enacarbil: A Randomized Controlled Study. Mayo Clinic Proceedings. 85(6). 512–521. 56 indexed citations

Thase, Michael E., Pierre V. Trân, Curtis G. Wiltse, et al.. (2005). Cardiovascular Profile of Duloxetine, a Dual Reuptake Inhibitor of Serotonin and Norepinephrine. Journal of Clinical Psychopharmacology. 25(2). 132–140. 94 indexed citations

Delgado, Pedro L., Stephen K. Brannan, Craig Mallinckrodt, et al.. (2005). Sexual Functioning Assessed in 4 Double-Blind Placebo- and Paroxetine-Controlled Trials of Duloxetine for Major Depressive Disorder. The Journal of Clinical Psychiatry. 66(6). 686–692. 115 indexed citations

Bymaster, Frank P., Robert K. McNamara, & Pierre V. Trân. (2003). New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert Opinion on Investigational Drugs. 12(4). 531–543. 45 indexed citations

Mallinckrodt, Craig, D. Goldstein, Michael J. Detke, Yili Lu, & Pierre V. Trân. (2003). Duloxetine. The Primary Care Companion For CNS Disorders. 5(1). 19–28. 54 indexed citations

Feldman, Peter D., Christopher Kaiser, John Kennedy, et al.. (2003). Comparison of Risperidone and Olanzapine in the Control of Negative Symptoms of Chronic Schizophrenia and Related Psychotic Disorders in Patients Aged 50 to 65 Years. The Journal of Clinical Psychiatry. 64(9). 998–1004. 26 indexed citations

Trân, Pierre V., Frank P. Bymaster, Robert K. McNamara, & William Z. Potter. (2003). Dual Monoamine Modulation for Improved Treatment of Major Depressive Disorder. Journal of Clinical Psychopharmacology. 23(1). 78–86. 104 indexed citations

Lee, Chien‐Te, et al.. (2002). Switching to Olanzapine From Previous Antipsychotics. The Journal of Clinical Psychiatry. 63(7). 569–576. 31 indexed citations

10.

Mazzotti, Guido, Wagner F. Gattaz, Jorge Ospina, et al.. (2001). Olanzapine as Alternative Therapy for Patients With Haloperidol-Induced Extrapyramidal Symptoms: Results of a Multicenter, Collaborative Trial in Latin America. Journal of Clinical Psychopharmacology. 21(4). 375–381. 31 indexed citations

11.

Zhang, Fan, P E Keck, Peter D. Feldman, et al.. (2001). Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. Journal of Affective Disorders. 67(1-3). 133–140. 21 indexed citations

12.

Tollefson, Gary D., Scott W. Andersen, & Pierre V. Trân. (1999). The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biological Psychiatry. 46(3). 365–373. 68 indexed citations

13.

Trân, Pierre V., Gary D. Tollefson, T.M. Sanger, et al.. (1999). Olanzapineversushaloperidol in the treatment of schizoaffective disorder. The British Journal of Psychiatry. 174(1). 15–22. 54 indexed citations

14.

Trân, Pierre V., et al.. (1998). Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. The British Journal of Psychiatry. 172(6). 499–505. 109 indexed citations

15.

Tollefson, Gary D. & Pierre V. Trân. (1998). Comments on "Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders" by Tran and Associates. Journal of Clinical Psychopharmacology. 18(4). 354–356. 1 indexed citations

16.

Tollefson, Gary D. & Pierre V. Trân. (1998). Comments on Article by Tran and Associates, "Double-Blind Comparison of Olanzapine Versus Risperidone in Treatment of Schizophrenia and Other Psychotic Disorders". Journal of Clinical Psychopharmacology. 18(2). 177–179. 4 indexed citations

17.

Trân, Pierre V., et al.. (1997). Extrapyramidal Symptoms and Tolerability of Olanzapine Versus Haloperidol in the Acute Treatment of Schizophrenia. The Journal of Clinical Psychiatry. 58(5). 205–211. 127 indexed citations

18.

Trân, Pierre V., S.H. Hamilton, Amy J. Kuntz, et al.. (1997). Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders. Journal of Clinical Psychopharmacology. 17(5). 407–418. 567 indexed citations breakdown →

19.

Beasley, Charles M., S.H. Hamilton, A.M. Crawford, et al.. (1997). Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology. 7(2). 125–137. 245 indexed citations

20.

Tollefson, Gary D., et al.. (1995). SAT-5-5 Olanzapine: An exciting atypical antipsychotic — the clinical experience. European Neuropsychopharmacology. 5(3). 256–256. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact